Q3 2025 Orion Oyj Earnings Call Transcript
Key Points
- Nubeqa received approval from the European Commission for use in metastatic hormone-sensitive prostate cancer, boosting its market potential.
- The Generics and Consumer Health business experienced a strong quarter, supported by good product availability and successful new launches.
- Base business growth was 24% year-over-year, with total net sales reaching EUR 423 million.
- Operating profit grew by 68% to EUR 121 million, indicating strong financial performance.
- Animal Health continued its growth trend, showing strong two-digit growth over the first nine months.
- ODM-105 tasipimidine Phase 2 trial for insomnia did not meet its efficacy target, leading to the discontinuation of the program.
- Branded Products growth was slow at 3% in Q3, mainly due to timing issues with deliveries to Stalevo partners.
- Fixed costs increased, primarily due to planned R&D and sales and marketing expenses.
- The company faced delays in deliveries for Branded Products and Animal Health, impacting quarterly performance.
- The milestone payments from Bayer and MSD in the previous year made year-over-year comparisons challenging, as these were not repeated in 2025.
Okay (spoken in foreign language) Good afternoon, and welcome to Orion's earnings conference call and webcast for the financial period of January-September 2025. My name is Tuukka Hirvonen. I'm the Head of Investor Relations here at Orion.
In a few moments, we will start with the presentation by our CEO and President, Ms. Liisa Hurme. After which then we will have a Q&A session where you can post questions both to Liisa and also to our CFO, René Lindell. (Event Instructions) And just before I let Liisa to take the stage, I'd like to draw your attention to this disclaimer regarding forward-looking statements. But with that, it's my pleasure to hand over to Liisa. Liisa?
Thank you, Tuukka, and welcome to Orion Q3 webcast on my behalf as well. Here are some highlights from quarter three 2025. Nubeqa received approval from European Commission for use of darolutamide and ADT, androgen deprivation
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
